NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · IEX Real-Time Price · USD
22.03
+0.57 (2.68%)
Apr 24, 2024, 1:12 PM EDT - Market open
Company Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V.
| Country | Netherlands |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Dr. Michael Harvey Davidson FACC, Facp., M.D. |
Contact Details
Address: Gooimeer 2-35 Narrden, P7 1411 DC Netherlands | |
| Phone | 35 206 2971 |
| Website | newamsterdampharma.com |
Stock Details
| Ticker Symbol | NAMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001936258 |
| ISIN Number | NL00150012L7 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President, Executive Board Member and Director |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board and Director |
| Mayur Amrat Somaiya | Chief Financial Officer |
| Juliette Audet M.B.A., M.Sc. | Chief Business Officer |
| Douglas F. Kling | Chief Operating Officer |
| Jim Jacobson | Chief Legal Officer and Secretary |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer |
| Dr. Sheng Cui Ph.D. | Vice President and Head of Chemistry Manufacturing and Controls (CMC) |
| Annie Neild | Vice President and Head of Regulatory Affairs |
| William Jones Jr., M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | 424B3 | Prospectus |
| Apr 17, 2024 | EFFECT | Notice of Effectiveness |
| Apr 12, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 144 | Filing |
| Mar 12, 2024 | 424B3 | Prospectus |
| Mar 8, 2024 | EFFECT | Notice of Effectiveness |
| Mar 4, 2024 | 8-K | Current Report |
| Mar 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 28, 2024 | POS AM | Post-Effective amendments for registration statement |